Literature DB >> 7091448

d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

D P van Kammen, W E Bunney, J P Docherty, S R Marder, M H Ebert, J E Rosenblatt, J N Rayner.   

Abstract

In this placebo-paired, double-blind study, 13 of 45 schizophrenic patients showed an acute improvement in schizophrenic symptoms following d-amphetamine infusion (20 mg). The 18 patients who worsened tended to have higher CSF 3-methoxy-4-hydroxyphenylglycol levels than did those who improved. d-Amphetamine blood levels and clinical descriptors of schizophrenic subgroups did not differentiate patients who improved from those who worsened; however, patients who improved had been significantly more psychotic before the infusion. Patients who worsened had been more psychotic than those who did not change. The authors suggest that those who did not change. The authors suggest that sensitivity to dopamine stimulation in schizophrenia is state-dependent rather than trait-dependent and that the simple, undirectional hypothesis of schizophrenia needs to be reformulated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7091448     DOI: 10.1176/ajp.139.8.991

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  15 in total

1.  Treatment refractory schizophrenia.

Authors:  J P Lindenmayer
Journal:  Psychiatr Q       Date:  2000

2.  Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects.

Authors:  N D Volkow; G J Wang; S J Gatley; J S Fowler; Y S Ding; J Logan; R Hitzemann; B Angrist; J Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 3.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

4.  Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat.

Authors:  S K Bhardwaj; P A Forcelli; G Palchik; K Gale; L K Srivastava; A Kondratyev
Journal:  Neuropharmacology       Date:  2012-02-15       Impact factor: 5.250

5.  Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.

Authors:  A Wolkin; B Angrist; A Wolf; J Brodie; B Wolkin; J Jaeger; R Cancro; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Amphetamine and negative symptoms of schizophrenia.

Authors:  M Sanfilipo; A Wolkin; B Angrist; D P van Kammen; E Duncan; S Wieland; T B Cooper; E D Peselow; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

7.  Amphetamine response and relapse risk after depot neuroleptic discontinuation.

Authors:  B Angrist; E Peselow; M Rubinstein; A Wolkin; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  d-Amphetamine raises cortisol levels in schizophrenic patients with and without chronic naltrexone pretreatment.

Authors:  D P van Kammen; S C Schulz
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

9.  D-amphetamine in obsessive-compulsive disorder.

Authors:  T R Insel; J A Hamilton; L B Guttmacher; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 10.  Pharmacological manipulation of human working memory.

Authors:  Deanna M Barch
Journal:  Psychopharmacology (Berl)       Date:  2004-01-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.